RxDoctor Payments Data

Charlene Moon, NP

Nurse Practitioner · Savannah, GANPI 1457414195

Payments from drug & device makers

$5,123in general payments, 2019–2025

Across 243 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$1K
  • Johnson & Johnson$655
  • Novo Nordisk$324
  • Merck$180
  • Janssen Products, LP$150
  • plus $698 from 7 others

What the payments were for

  • Food & beverage$4,97397%
  • Education$1503%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,123 in reported general payments places this provider in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$1,715
Medicare patients
13
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DovatoDolutegravir Sodium/Lamivudine127$373,972
BiktarvyBictegrav/Emtricit/Tenofov Ala84$339,707
TivicayDolutegravir Sodium79$213,751
JulucaDolutegravir/Rilpivirine51$179,097
TriumeqAbacavir/Dolutegravir/Lamivudi49$158,423
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf26$117,325
DescovyEmtricitabine/Tenofov Alafenam58$110,185
OdefseyEmtricitab/Rilpiviri/Tenof Ala30$108,247
PrezcobixDarunavir/Cobicistat36$85,879
PifeltroDoravirine23$38,372
JanuviaSitagliptin Phosphate22$10,848
Atovaquone19$9,580
Ritonavir16$2,682
SymbicortBudesonide/Formoterol Fumarate12$2,643
Ventolin HfaAlbuterol Sulfate32$1,715

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Tivicay, Juluca, Triumeq$1,874$925,243306 claims
GileadBiktarvy, Descovy$1,242$449,892142 claims
Janssen Products, LPSymtuza$150$117,32526 claims
Johnson & JohnsonPrezcobix$655$85,87936 claims
MerckPifeltro, Januvia$180$49,22045 claims
AstraZenecaSymbicort$109$2,64312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →